Precipio Inc(PRPO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.68 | Insider Own | 12.59% | Shs Outstand | 1.8M | Perf Week | 4.59% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | - | Insider Trans | -1.75% | Shs Float | 1.6M | Perf Month | 21.21% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | - | Inst Own | 17.69% | Short Float | 3.91% | Perf Quarter | 20.72% |
| Income | -0.00B | P/S | 1.8 | EPS this Y | - | Inst Trans | 0.87% | Short Ratio | 0.54 | Perf Half Y | -5.06% |
| Sales | 0.03B | P/B | 3.31 | EPS next 5Y | - | ROA | -6.05% | Short Interest | 0.06M | Perf YTD | 18.89% |
| Book/sh | 8.25 | P/C | 15.88 | EPS past 3/5Y | 72.37% 57.83% | ROE | -8.98% | 52W High | -18.76% ($33.63) | Perf Year | 35.04% |
| Cash/sh | 1.72 | P/FCF | 61.9 | Sales past 3/5Y | 36.71% 31.6% | ROIC | -6.9% | 52W Low | 70.75% ($16.00) | Perf 3Y | 380.99% |
| Dividend Est. | - | EV/EBITDA | 170.39 | EPS Y/Y TTM | 43.26% | Gross Margin | 37.35% | Volatility(W/M) | 9.07% 8.63% | Perf 5Y | -56.22% |
| Dividend TTM | - | EV/Sales | 1.82 | Sales Y/Y TTM | 28.04% | Oper. Margin | -5.68% | ATR (14) | 2.08 | Perf 10Y | -98.95% |
| Dividend Ex-Date | - | Quick Ratio | 1.56 | EPS Q/Q | -365.15% | Profit Margin | -4.47% | RSI (14) | 53.31 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.77 | Sales Q/Q | 24.18% | SMA20 | -1.35% ($27.69) | Beta | 1.29 | Target Price | $19 |
| Payout | - | Debt/Eq | 0.24 | Earnings | 2026/8/14 | SMA50 | 8.29% ($25.23) | Rel Volume | 0.79 | Prev Close | $26.91 |
| Employees | 61 | LT Debt/Eq | 0.19 | EPS/Sales Surpr. | - | SMA200 | 8.59% ($25.16) | Avg Volume(3M) | 0.11M | Price | $27.32 |
| IPO | 2000/7/18 | Option/Short | No/Yes | Trades | 984 | Volume | 89,113 | Change | 1.52% |
Company
PRPO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🔬 Presiceo is a cancer diagnostics company focused on blood cancer diagnostics. It combines pathology services with its proprietary products, HemeScreen (a blood cancer mutation panel) and IV-Cell, to enhance diagnostic accuracy and cost efficiency, and its revenue has been growing rapidly recently.
Over the past 1 year, roughly in the middle
19% below its 1-year high.
PRPO has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +381.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 17.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
DCOR 0.00%
DFAS 0.00%
DFSU 0.00%
VTI 0.00%It ranks #4 in the industry
Based on market cap of $49M.
PRPO $49M PER -
TMO $225B PER 32.8
DHR $141B PER 35.5
NTRA $47B PER -
FAQ
What kind of company is PRPO?
PRPO belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of PRPO?
The market cap of PRPO is approximately $49M, ranking 4,948 within its sector.
What is the 52-week high and low for PRPO?
PRPO has recorded a 52-week high of $33.63 and a low of $16.00.
